Axonyx Inc., of New York, reported data showing an increase in brain glucose metabolism and reduction of brain amyloid levels in the memory and cognition areas in brains of mild-to-moderate Alzheimer s disease patients treated with Phenserine 15 mg twice daily for 13-weeks. The data were included in an oral presentation by Agneta Nordberg of the Karolinska Institute in Stockholm, Sweden, on Friday.

GTx Inc., of Memphis, Tenn., started a separate Phase IIIb trial as an extension of the pivotal Phase III ADT clinical trial of Acapodene (toremifene citrate) in an 80 mg dose for the treatment of multiple serious side effects of androgen deprivation therapy. Prostate cancer patients in the ADT trial who have completed the full two-year treatment will be eligible for an additional year of treatment with the extension trial. The additional study will not affect the current timeline for the completion of the ongoing Phase III trial in the second half of 2007 and the potential submission of the new drug application.

Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., reported an updated review of safety data for its ongoing multicenter Phase II trial of NX-1207, showing no serious drug side effects. NX-1207 is Nymox s lead drug candidate for benign prostatic hyperplasia.

Theravance Inc., of South San Francisco, said GlaxoSmithKline plc, of London, enrolled the first patient in a Phase IIb program with the investigational long-acting beta agonist compound, 159797, from the companies Beyond Advair collaboration, in patients with mild to moderate asthma. In the collaboration with GSK, the plan is to develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid.

Viral Genetics Inc., of Azusa, Calif., which is developing the biological therapy VGV-1 for the treatment of HIV infection, said it expects no significant delay in the release of the results of the Phase III trial conducted in South Africa. The TNP-001 study involves 137 HIV positive patients treated with either VGV-1 or placebo that began enrollment in August 2004 and completed follow up in November 2005. Viral Genetics separately said it does not know why the company s stock has been declining in the past week and would not comment on the subject. Shares (OTC BB:VRAL) closed Friday at 65 cents, up 12 cents, or 22.6 percent.